Last reviewed · How we verify
Intranasal capsaicin — Competitive Intelligence Brief
phase 3
TRPV1 agonist / Topical analgesic
TRPV1 (Transient Receptor Potential Vanilloid 1)
Neurology / Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Intranasal capsaicin (Intranasal capsaicin) — The University of Texas Health Science Center, Houston. Intranasal capsaicin activates TRPV1 nociceptors in the nasal mucosa to desensitize pain-sensing nerve fibers and reduce neurogenic inflammation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intranasal capsaicin TARGET | Intranasal capsaicin | The University of Texas Health Science Center, Houston | phase 3 | TRPV1 agonist / Topical analgesic | TRPV1 (Transient Receptor Potential Vanilloid 1) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (TRPV1 agonist / Topical analgesic class)
- The University of Texas Health Science Center, Houston · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intranasal capsaicin CI watch — RSS
- Intranasal capsaicin CI watch — Atom
- Intranasal capsaicin CI watch — JSON
- Intranasal capsaicin alone — RSS
- Whole TRPV1 agonist / Topical analgesic class — RSS
Cite this brief
Drug Landscape (2026). Intranasal capsaicin — Competitive Intelligence Brief. https://druglandscape.com/ci/intranasal-capsaicin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing